Clinical Trial Detail

NCT ID NCT02453620
Title Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

Her2-receptor negative breast cancer

Advanced Solid Tumor

Therapies

Entinostat + Ipilimumab + Nivolumab

Age Groups: adult senior

Additional content available in CKB BOOST